arsenic has been researched along with valproic acid in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, LP; Lin, CM; Lin, FA; Shen, JZ; Ye, BG | 1 |
| Jiang, J; Liu, XS; Peng, CY; Zheng, HT | 1 |
| Liu, L; Qu, X; Wang, P; Wang, X; Zeng, H; Zhu, H; Zhu, X | 1 |
| Wang, XN; Zhang, M | 1 |
| Alvarez, EM; Blanco, GA; Cavaliere, V; Costantino, SN; Kornblihtt, L; Lombardo, T | 1 |
| Wang, X; Zhang, M | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
7 other study(ies) available for arsenic and valproic acid
| Article | Year |
|---|---|
[Synergistic effects of VPA and As2O3 on Molt-4 cells in vitro and its possible mechanisms].
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p15; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Oxides; Up-Regulation; Valproic Acid | 2008 |
Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Drug Antagonism; Drug Synergism; Electrophoresis, Capillary; Growth Inhibitors; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; K562 Cells; Leukemia; Oxides; U937 Cells; Valproic Acid | 2010 |
As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Cells, Cultured; Dose-Response Relationship, Drug; Genes, Reporter; HEK293 Cells; HIV Long Terminal Repeat; HIV-1; Humans; Jurkat Cells; Leukocytes, Mononuclear; Microscopy, Fluorescence; NF-kappa B; Oxides; Phorbol Esters; Signal Transduction; Transfection; Tumor Necrosis Factor-alpha; Valproic Acid; Virus Activation; Virus Latency | 2013 |
[Apoptosis-inducing effect of valproic acid combined with arsenic trioxide on RPMI 8226 cells and its mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Valproic Acid | 2014 |
Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Humans; Leupeptins; Membrane Potential, Mitochondrial; Membrane Potentials; Membrane Proteins; Mitochondria; Oxides; Proto-Oncogene Proteins; U937 Cells; Up-Regulation; Valproic Acid; Vincristine | 2014 |
Synergistic effects of valproic acid and arsenic trioxide on RPMI8226 cells in vitro and the possible underlying mechanisms.
Topics: Acetylation; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Valproic Acid | 2015 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |